A Pan-TB Regimen Targeting Host and Microbe

Last updated: October 3, 2024
Sponsor: The Aurum Institute NPC
Overall Status: Active - Recruiting

Phase

2/3

Condition

Hiv

Lung Disease

Treatment

Bedaquiline

N-acetyl cysteine

Pretomanid

Clinical Study ID

NCT05686356
AUR1-1-312
6986
RIA2019AMR-2647
24206
  • Ages 18-65
  • All Genders

Study Summary

This project will develop the first regimen meeting WHO criteria for a pan-TB indication, ie, not requiring knowledge of RIF susceptibility. The regimen will test sutezolid at 2 dose levels, with the approved anti-TB drugs bedaquiline and pretomanid, in a phase 2c trial. It will also test whether the addition of N-acetylcysteine (NAC), a re-purposed host-directed WHO essential medicine, can protect the lung and liver against oxidative damage, preserve lung function, and accelerate the eradication of MTB infection by replenishing glutathione (GSH).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Aged 18 to 65 years

  2. Willing and able to provide signed written consent prior to undertaking anytrial-related procedures, or, in the case of illiteracy, witnessed oral consent

  3. Body weight (in light clothing without shoes) between 30 and 90 kg.

  4. Radiographic evidence of pulmonary tuberculosis

  5. Positive Xpert TB/RIF (original or Ultra) for MTB

  6. RIF susceptibility diagnosed by Xpert TB/RIF, with subsequent culture confirmation

  7. If sexually active, willing to use an effective contraceptive method for theduration of tuberculosis treatment

  8. HIV-1 seronegative, or if HIV-1 seropositive, CD4 T cell count ≥100/µl and eitherreceiving ART or willing to start ART during study participation

  9. SARS-CoV-2 PCR or antigen test negative, or if positive, either fully vaccinatedagainst Covid-19 or with D-dimer <0.8 ug/ml

  10. Willing to adhere to a diet excluding tyramine-rich foods (certain mold-ripenedcheeses and cured meats), and to avoid eating grapefruits and pomelos

Exclusion

Exclusion Criteria:

  1. Any condition for which participation in the trial, as judged by the investigator,could compromise the well-being of the subject or prevent, limit or confoundprotocol specified assessments

  2. Current or imminent (within 24 hr) treatment for malaria.

  3. Pregnant or nursing

  4. Is critically ill, and in the judgment of the investigator has a diagnosis likely toresult in death during the trial or the follow-up period.

  5. TB meningitis or spondylitis, or other forms of severe tuberculosis with high riskof a poor outcome as judged by the investigator.

  6. History of allergy or hypersensitivity to any of the trial therapies or relatedsubstances.

  7. Having participated in other clinical trials with investigational agents within 8weeks prior to trial start or currently enrolled in an investigational trial.

  8. Prior TB treatment in the preceding 6 months

  9. Angina pectoris requiring treatment with nitroglycerin or other nitrates

  10. Cardiac arrhythmia requiring medication, or any clinically significant ECGabnormality, in the opinion of the investigator

  11. History of unstable Diabetes Mellitus requiring hospitalization for hyper- orhypo-glycaemia within the past year prior to start of screening.

  12. Use of systemic corticosteroids within the past 28 days.

  13. Patients requiring treatment with medications not compatible with rifampin, such asHIV-1 protease inhibitors

  14. Patients requiring treatment with antidepressants, including MAO inhibitors andSSRIs.

  15. Subjects with any of the following abnormal laboratory values:

  16. HBsAg positive

  17. creatinine >2 mg/dL

  18. hemoglobin <8 g/dL

  19. platelets <100x109 cells/L

  20. serum potassium <3.5 mM/L

  21. alanine aminotransferase (ALT) ≥2.0 x ULN

  22. alkaline phosphatase (AP) >5.0 x ULN

  23. total bilirubin >1.5 mg/dL

  24. random blood glucose >200 mg/dL

Study Design

Total Participants: 352
Treatment Group(s): 5
Primary Treatment: Bedaquiline
Phase: 2/3
Study Start date:
July 28, 2023
Estimated Completion Date:
September 30, 2025

Connect with a study center

  • Instituto Nacional de Saúde

    Maputo,
    Mozambique

    Active - Recruiting

  • Clinical HIV Research Unit

    Johannesburg, Gauteng 2092
    South Africa

    Active - Recruiting

  • The Clinical HIV Research Unit

    Johannesburg, Gauteng 2092
    South Africa

    Site Not Available

  • The Aurum Institute: Tembisa Clinical Research Centre

    Tembisa, Gauteng 1632
    South Africa

    Active - Recruiting

  • The Aurum Institute, Rustenburg Clinical Research Centre

    Rustenburg, North West Provice 0299
    South Africa

    Active - Recruiting

  • TASK Eden

    George, Western Cape 6529
    South Africa

    Active - Recruiting

  • Clinical HIV Research Unit

    Durban, 4015
    South Africa

    Active - Recruiting

  • The Aurum Institute, Gavin J Churchyard Legacy Centre (Klerksdorp Clinical Research Centre)

    Klerksdorp, 2571
    South Africa

    Active - Recruiting

  • NIMR-Mbeya Medical Research Centre

    Mbeya,
    Tanzania

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.